NCT06582277View on ClinicalTrials.gov

Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

June 2, 2025

Study Completion Date

June 2, 2025

Conditions
Vaccine-Preventable DiseasesInfluenza
Interventions
BIOLOGICAL

OVX836 shot

One single administration intramuscularly at Day 1.

Trial Locations (1)

Unknown

Centre for Vaccinology (CEVAC) Ghent University Hospital, Ghent

Sponsors

Lead Sponsor

Osivax
All Listed Sponsors
collaborator

Harmony Clinical Research BVBA

OTHER

collaborator

Clinfidence

UNKNOWN

collaborator

Inferential

INDUSTRY

collaborator

University Hospital, Ghent

OTHER

collaborator

KCAS Bio

UNKNOWN

lead

Osivax

INDUSTRY